2025
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
Costa P, Pilat M, Rodon Ahnert J, Burgess M, Tinoco G, Close J, Groisberg R, Subbiah V, Powers B, Haddox C, Grilley-Olson J, Keedy V, Li J, Ivy S, Patel A, Shapiro G, Ishizuka J, Schalper K, LoRusso P. A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. Journal Of Clinical Oncology 2025, 43: 3087-3087. DOI: 10.1200/jco.2025.43.16_suppl.3087.Peer-Reviewed Original ResearchProgression-free survivalSolid tumorsOverall survivalClinical benefitOpen-label phase II clinical trialSolid tumors refractory to standard treatmentMedian progression-free survivalRefractory to standard treatmentIDH mutant tumorsPhase II clinical trialBRCA-mutated cancersEfficacy of olaparibPhase 2 studyPhase II trialFollow-up timePre-clinical dataII clinical trialsPre-clinical evidenceImpaired homologous recombinationClinical Trials NetworkAdvanced chondrosarcomaMedian OSII trialIDH1/2 mutationsMedian ageA phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
Costa P, Hafez N, Pilat M, Kalyan A, Azad N, Gore S, Shields A, Al Hallak M, Jin N, Malalur P, Hays J, Rodon Ahnert J, Schalper K, LoRusso P. A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors. Journal Of Clinical Oncology 2025, 43: 3089-3089. DOI: 10.1200/jco.2025.43.16_suppl.3089.Peer-Reviewed Original ResearchProgression-free survivalSolid tumorsOverall survivalClinical benefitOpen-label phase II clinical trialSolid tumors refractory to standard treatmentMedian progression-free survivalRefractory to standard treatmentNational Clinical Trials NetworkPhase II clinical trialCombination of olaparibEfficacy of olaparibLower-grade tumorsLow-grade tumorsPhase 2 studyNCI's National Clinical Trials NetworkFollow-up timePre-clinical dataII clinical trialsIsocitrate dehydrogenase mutationPre-clinical evidenceClinical Trials NetworkMedian OSStable diseaseImpaired homologous recombination repair
2020
Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.
LoRusso P, Pilat M, Santa-Maria C, Connolly R, Roesch E, Afghahi A, Han H, Nanda R, Wulf G, Assad H, Park H, Dees E, Force J, Noonan A, Brufsky A, Abramson V, Haley B, Buys S, Sharon E, Schalper K. Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer. Journal Of Clinical Oncology 2020, 38: tps1102-tps1102. DOI: 10.1200/jco.2020.38.15_suppl.tps1102.Peer-Reviewed Original ResearchPositive breast cancerPo bidPARP inhibitionBreast cancerImmune responseOpen-label phase II clinical trialAdaptive anti-tumor immune responsesAnti-tumor immune responsePhase II clinical trialMarked lymphocyte infiltrationPD-1 blockadePD-L1 expressionPre-treatment biopsiesProgression-free survivalAntitumor immune responseImmune checkpoint blockadeMajority of patientsBRCA 1/2 mutationsTumor immune contextureBiopsy time pointsHomologous DNA repairPARP inhibitor olaparibMonotherapy armCombination armImmune contexture
2016
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Research And Treatment 2016, 158: 485-495. PMID: 27393622, PMCID: PMC4963434, DOI: 10.1007/s10549-016-3889-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEvent-free survivalAddition of bevacizumabInflammatory breast cancerAdvanced breast cancerDose-dense doxorubicinNab-paclitaxelPathologic complete responseBreast cancerPCR rateOverall survivalOpen-label phase II clinical trialHormone receptor-positive diseaseImproved event-free survivalPathologic complete response ratePhase II clinical trialNeoadjuvant chemotherapy armNeoadjuvant nab-paclitaxelRole of bevacizumabWeekly nab-paclitaxelComplete response rateReceptor-positive diseaseHormone receptor statusSequence of administrationChemotherapy arm
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply